7NRO | pdb_00007nro

Crystal structure of AlkB in complex with manganese and N-(4-((6-((carboxymethyl)carbamoyl)-5-hydroxypyridin-2-yl)amino)phenyl)-N-oxohydroxylammonium


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.25 Å
  • R-Value Free: 
    0.164 (Depositor), 0.163 (DCC) 
  • R-Value Work: 
    0.146 (Depositor), 0.146 (DCC) 
  • R-Value Observed: 
    0.147 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 7NRO

Ligand Structure Quality Assessment 


This is version 2.0 of the entry. See complete history

Literature

Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.

Shishodia, S.Demetriades, M.Zhang, D.Tam, N.Y.Maheswaran, P.Clunie-O'Connor, C.Tumber, A.Leung, I.K.H.Ng, Y.M.Leissing, T.M.El-Sagheer, A.H.Salah, E.Brown, T.Aik, W.S.McDonough, M.A.Schofield, C.J.

(2021) J Med Chem 64: 16609-16625

  • DOI: https://doi.org/10.1021/acs.jmedchem.1c01204
  • Primary Citation Related Structures: 
    4QHO, 7E8Z, 7NRO

  • PubMed Abstract: 

    FTO catalyzes the Fe(II) and 2-oxoglutarate (2OG)-dependent modification of nucleic acids, including the demethylation of N 6 -methyladenosine (m 6 A) in mRNA. FTO is a proposed target for anti-cancer therapy. Using information from crystal structures of FTO in complex with 2OG and substrate mimics, we designed and synthesized two series of FTO inhibitors, which were characterized by turnover and binding assays, and by X-ray crystallography with FTO and the related bacterial enzyme AlkB. A potent inhibitor employing binding interactions spanning the FTO 2OG and substrate binding sites was identified. Selectivity over other clinically targeted 2OG oxygenases was demonstrated, including with respect to the hypoxia-inducible factor prolyl and asparaginyl hydroxylases (PHD2 and FIH) and selected JmjC histone demethylases (KDMs). The results illustrate how structure-based design can enable the identification of potent and selective 2OG oxygenase inhibitors and will be useful for the development of FTO inhibitors for use in vivo .


  • Organizational Affiliation
    • The Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, U.K.

Macromolecule Content 

  • Total Structure Weight: 24.49 kDa 
  • Atom Count: 1,952 
  • Modeled Residue Count: 202 
  • Deposited Residue Count: 216 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Alpha-ketoglutarate-dependent dioxygenase AlkB216Escherichia coli K-12Mutation(s): 0 
Gene Names: alkBaidDb2212JW2200
EC: 1.14.11.33
UniProt
Find proteins for P05050 (Escherichia coli (strain K12))
Explore P05050 
Go to UniProtKB:  P05050
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP05050
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
HZX
(Subject of Investigation/LOI)

Query on HZX



Download:Ideal Coordinates CCD File
B [auth A]2-[[6-[(4-nitrophenyl)amino]-3-oxidanyl-pyridin-2-yl]carbonylamino]ethanoic acid
C14 H12 N4 O6
ITMKUXMZMOBJES-UHFFFAOYSA-N
MN

Query on MN



Download:Ideal Coordinates CCD File
C [auth A]MANGANESE (II) ION
Mn
WAEMQWOKJMHJLA-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.25 Å
  • R-Value Free:  0.164 (Depositor), 0.163 (DCC) 
  • R-Value Work:  0.146 (Depositor), 0.146 (DCC) 
  • R-Value Observed: 0.147 (Depositor) 
Space Group: P 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 36.88α = 77.6
b = 38.75β = 75.38
c = 40.25γ = 66.14
Software Package:
Software NamePurpose
PHENIXrefinement
xia2data reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Wellcome TrustUnited Kingdom--

Revision History  (Full details and data files)

  • Version 1.0: 2021-10-13
    Type: Initial release
  • Version 1.1: 2021-11-24
    Changes: Data collection, Database references, Structure summary
  • Version 1.2: 2021-12-08
    Changes: Data collection, Database references
  • Version 1.3: 2024-01-31
    Changes: Data collection, Refinement description
  • Version 2.0: 2026-04-15
    Changes: Atomic model, Author supporting evidence, Data collection, Derived calculations, Non-polymer description, Structure summary